ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
New Myostatin Inhibitor
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Jinzang" data-source="post: 187134" data-attributes="member: 12925"><p>There was recently an <a href="https://www.npr.org/sections/health-shots/2020/09/08/910776985/drug-that-bulked-up-mice-in-space-might-someday-help-astronauts-make-long-voyage" target="_blank">article in the news</a> about mice who were flown on the International Space Station who resisted the normal loss of muscle mass associated with weightlessness as a result of receiving a drug containing a new myostatin inhibitor. The mice not only resisted muscle loss, they gained muscle and bone density, developing twice the amount of muscle as normal mice. The <a href="https://www.pnas.org/content/early/2020/09/01/2014716117" target="_blank">journal article</a> describing the study calls the myostatin inhibitor "A decoy receptor (ACVR2B/Fc) consisting of the extracellular, ligand-binding domain of ACVR2B fused to an immunoglobulin Fc domain." The journal article goes on to say the drug "can induce significant muscle growth when given systemically to wild type mice. Indeed, by blocking both ligands, this decoy receptor can induce significantly more muscle growth than other MSTN inhibitors, and at high doses, ACVR2B/Fc can induce over 50% muscle growth in just 2 wk. Moreover, because this decoy receptor can block not only MSTN but also activin A, systemic administration of ACVR2B/Fc can also lead to significant increases in bone density. The dual ability of ACVR2B/Fc to promote muscle growth and to increase bone density has suggested the possibility that this therapeutic strategy may be particularly useful to combat simultaneously comorbid muscle and bone loss, and indeed, this strategy has been shown to be effective in a mouse model of osteogenesis imperfecta, which is characterized by both muscle atrophy and bone fragility."</p><p></p><p>It seems the pharmaceutical companies, as well as the peptide "research suppliers" should be all over this.</p></blockquote><p></p>
[QUOTE="Jinzang, post: 187134, member: 12925"] There was recently an [URL='https://www.npr.org/sections/health-shots/2020/09/08/910776985/drug-that-bulked-up-mice-in-space-might-someday-help-astronauts-make-long-voyage']article in the news[/URL] about mice who were flown on the International Space Station who resisted the normal loss of muscle mass associated with weightlessness as a result of receiving a drug containing a new myostatin inhibitor. The mice not only resisted muscle loss, they gained muscle and bone density, developing twice the amount of muscle as normal mice. The [URL='https://www.pnas.org/content/early/2020/09/01/2014716117']journal article[/URL] describing the study calls the myostatin inhibitor "A decoy receptor (ACVR2B/Fc) consisting of the extracellular, ligand-binding domain of ACVR2B fused to an immunoglobulin Fc domain." The journal article goes on to say the drug "can induce significant muscle growth when given systemically to wild type mice. Indeed, by blocking both ligands, this decoy receptor can induce significantly more muscle growth than other MSTN inhibitors, and at high doses, ACVR2B/Fc can induce over 50% muscle growth in just 2 wk. Moreover, because this decoy receptor can block not only MSTN but also activin A, systemic administration of ACVR2B/Fc can also lead to significant increases in bone density. The dual ability of ACVR2B/Fc to promote muscle growth and to increase bone density has suggested the possibility that this therapeutic strategy may be particularly useful to combat simultaneously comorbid muscle and bone loss, and indeed, this strategy has been shown to be effective in a mouse model of osteogenesis imperfecta, which is characterized by both muscle atrophy and bone fragility." It seems the pharmaceutical companies, as well as the peptide "research suppliers" should be all over this. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
New Myostatin Inhibitor
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top